COMPOSITION: Moxifloxacin hydrochloride 400 mg
On average, adults have two or three colds a year and children have six to ten colds a year, of which only about 2% are complicated by acute bacterial sinusitis.
Drug class: Fluoroquinolones
- A 4th generation fluoroquinolone with a broad spectrum of activity against microorganisms isolated in Community Acquired Pneumonia (CAP), including multi-resistant pneumococci and pathogens such as M. catarrhalis and H. influenzae with resistance to penicillins, macrolides, and tetracyclines.
- Provided excellent clinical and bacteriological cure rates in CAP due to drug-resistant Streptococcus pneumococci.
- A better microbiological effect and lower risk of treatment failures of moxifloxacin can be attributed to its excellent tissue penetration, high bioavailability, and bactericidal mechanism.
- Possesses activity against atypical pathogens and meta-analysis data suggests that it alone has a higher pathogen eradication rate than β-lactam-based combination therapy.
- Moxifloxacin was as clinically equivalent and bacteriologically superior to the antibiotic regimens routinely used in patients with Acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease.